This inventor holds 1 USPTO granted patent. Top assignees: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts, Medigene Ag. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 168 
1 out of 48 
Years Active: 2016
Title: Silke Baerreiter: Innovator in Tumor Treatment
Introduction
Silke Baerreiter is a prominent inventor based in Weinheim, Germany. She has made significant contributions to the field of medical research, particularly in the treatment of tumors. Her innovative work has led to the development of a specific anti-L1 antibody that holds promise for cancer therapy.
Latest Patents
Silke Baerreiter holds 1 patent for her invention titled "Treatment of tumors using specific anti-L1 antibody." This patent relates to the anti-L1 monoclonal antibody 9.3, along with related antibodies or binding molecules. The invention focuses on the uses of these antibodies, especially in the context of tumor treatment.
Career Highlights
Throughout her career, Silke has worked with notable organizations, including Medigene AG and Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. Her experience in these institutions has allowed her to advance her research and contribute to significant medical advancements.
Collaborations
Silke has collaborated with esteemed colleagues such as Daniela Kelm and Peter Altevogt. These partnerships have enriched her research and expanded the impact of her work in the field of oncology.
Conclusion
Silke Baerreiter's innovative contributions to tumor treatment through her patented anti-L1 antibody exemplify her dedication to advancing medical science. Her work continues to inspire future research in cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile